{"id":19165,"date":"2024-05-04T15:39:27","date_gmt":"2024-05-04T19:39:27","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?p=19165"},"modified":"2025-01-29T09:23:02","modified_gmt":"2025-01-29T14:23:02","slug":"sentynl","status":"publish","type":"post","link":"https:\/\/www.progeriaresearch.org\/ar\/2024\/05\/04\/sentynl\/","title":{"rendered":"\u062a\u062a\u0639\u0627\u0648\u0646 PRF \u0627\u0644\u0622\u0646 \u0645\u0639 \u0634\u0631\u0643\u0629 Sentynl Therapeutics\u060c \u0627\u0644\u0645\u0627\u0644\u0643 \u0627\u0644\u0639\u0627\u0644\u0645\u064a \u0627\u0644\u062c\u062f\u064a\u062f \u0644\u0639\u0644\u0627\u062c lonafarnib (Zokinvy\u00a9)"},"content":{"rendered":"<p>[et_pb_section fb_built=\u201d1\u2033 _builder_version=\u201d4.16\u2033 global_colors_info=\u201d{}\u201d][et_pb_row _builder_version=\u201d4.16\u2033 background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d global_colors_info=\u201d{}\u201d][et_pb_column type=\u201d4_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_image src=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/static1.squarespace.webp\u201d title_text=\u201dstatic1.squarespace\u201d url=\u201dhttps:\/\/www.charitynavigator.org\/ein\/043460220\u2033 align=\u201dcenter\u201d admin_label=\u201dSentynl\u201d _builder_version=\u201d4.24.3\u2033 _module_preset=\u201ddefault\u201d width=\u201d50%\u201d max_width=\u201d50%\u201d global_colors_info=\u201d{}\u201d][\/et_pb_image][et_pb_text _builder_version=\u201d4.24.3\u2033 \u062d\u062c\u0645_\u062e\u0637_\u0627\u0644\u0646\u0635=\u201d18px\u201d \u062d\u062c\u0645_\u0627\u0644\u062e\u0644\u0641\u064a\u0629=\u201d\u0627\u0628\u062a\u062f\u0627\u0626\u064a\u201d \u0645\u0648\u0636\u0639_\u0627\u0644\u062e\u0644\u0641\u064a\u0629=\u201d\u0623\u0639\u0644\u0649_\u064a\u0633\u0627\u0631\u201d \u062a\u0643\u0631\u0627\u0631_\u0627\u0644\u062e\u0644\u0641\u064a\u0629=\u201d\u062a\u0643\u0631\u0627\u0631\u201d \u0645\u0639\u0644\u0648\u0645\u0627\u062a_\u0627\u0644\u0623\u0644\u0648\u0627\u0646_\u0627\u0644\u0639\u0627\u0645\u0629=\u201d{}\u201d]<\/p>\n<p>\u0633\u0627\u0631\u064a \u0627\u0644\u0645\u0641\u0639\u0648\u0644 \u0627\u0639\u062a\u0628\u0627\u0631\u064b\u0627 \u0645\u0646 \u0627\u0644\u062c\u0645\u0639\u0629 3 \u0645\u0627\u064a\u0648<sup>\u0631<\/sup>, 2024, <a href=\"https:\/\/url2.mailanyone.net\/scanner?m=1rzcKM-0009Dy-3G&amp;d=4%7Cmail%2F90%2F1713963600%2F1rzcKM-0009Dy-3G%7Cin2m%7C57e1b682%7C18374732%7C14629442%7C662903CE3D97FA99FA9E3F52842D032F&amp;o=%2Fphte%3A%2Fstsonnt%2F.cmyl&amp;s=pj636_P9eRvPUtyP8VtSjuVNKfg\">\u0634\u0631\u0643\u0629 \u0633\u064a\u0646\u062a\u064a\u0646\u0644 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633<\/a> \u0627\u0633\u062a\u062d\u0648\u0630\u062a \u0634\u0631\u0643\u0629 (Sentynl)\u060c \u0648\u0647\u064a \u0634\u0631\u0643\u0629 \u0623\u062f\u0648\u064a\u0629 \u062d\u064a\u0648\u064a\u0629 \u0645\u0642\u0631\u0647\u0627 \u0627\u0644\u0648\u0644\u0627\u064a\u0627\u062a \u0627\u0644\u0645\u062a\u062d\u062f\u0629 \u0648\u0645\u0645\u0644\u0648\u0643\u0629 \u0628\u0627\u0644\u0643\u0627\u0645\u0644 \u0644\u0634\u0631\u0643\u0629 Zydus Lifesciences, Ltd\u060c \u0639\u0644\u0649 \u0627\u0644\u062d\u0642\u0648\u0642 \u0627\u0644\u0639\u0627\u0644\u0645\u064a\u0629 \u0644\u0639\u0642\u0627\u0631 lonafarnib (Zokinvy) \u0645\u0646 \u0634\u0631\u0643\u0629 Eiger BioPharmaceuticals (Eiger). \u064a\u062a\u0645 \u062a\u0648\u0641\u064a\u0631 \u0639\u0642\u0627\u0631 Zokinvy\u00ae \u0644\u0644\u0623\u0633\u0631 \u0641\u064a \u062c\u0645\u064a\u0639 \u0623\u0646\u062d\u0627\u0621 \u0627\u0644\u0639\u0627\u0644\u0645 \u0627\u0644\u062a\u064a \u062a\u0633\u062a\u062e\u062f\u0645 \u0627\u0644\u0639\u0642\u0627\u0631 \u0643\u0639\u0644\u0627\u062c \u0644\u0645\u0631\u0636 \u0627\u0644\u0634\u064a\u062e\u0648\u062e\u0629 \u0627\u0644\u0645\u0628\u0643\u0631\u0629.<\/p>\n<p>\u062a\u062a\u062e\u0630 \u0634\u0631\u0643\u0629 Sentynl \u0645\u0646 \u0633\u0627\u0646 \u062f\u064a\u064a\u063a\u0648\u060c \u0643\u0627\u0644\u064a\u0641\u0648\u0631\u0646\u064a\u0627\u060c \u0645\u0642\u0631\u064b\u0627 \u0644\u0647\u0627\u060c \u0648\u0647\u064a \u062a\u0631\u0643\u0632 \u0639\u0644\u0649 \u062a\u0648\u0641\u064a\u0631 \u0623\u062f\u0648\u064a\u0629 \u0628\u064a\u0648\u0644\u0648\u062c\u064a\u0629 \u0635\u064a\u062f\u0644\u0627\u0646\u064a\u0629 \u062c\u062f\u064a\u062f\u0629 \u062a\u0639\u0645\u0644 \u0639\u0644\u0649 \u0625\u0637\u0627\u0644\u0629 \u0623\u0648 \u062a\u062d\u0633\u064a\u0646 \u0623\u0648 \u062a\u0639\u0632\u064a\u0632 \u062d\u064a\u0627\u0629 \u0627\u0644\u0623\u0634\u062e\u0627\u0635 \u0627\u0644\u0645\u0635\u0627\u0628\u064a\u0646 \u0628\u0623\u0645\u0631\u0627\u0636 \u0646\u0627\u062f\u0631\u0629 (https:\/\/sentynl.com\/). \u0648\u062a\u0639\u0631\u0628 \u0634\u0631\u0643\u0629 PRF \u0639\u0646 \u0627\u0645\u062a\u0646\u0627\u0646\u0647\u0627 \u0644\u0644\u0634\u0631\u0627\u0643\u0629 \u0627\u0644\u0646\u0627\u062c\u062d\u0629 \u0645\u0639 \u0634\u0631\u0643\u0629 Eiger\u060c \u0648\u0647\u064a \u0645\u062a\u062d\u0645\u0633\u0629 \u0627\u0644\u0622\u0646 \u0644\u0644\u0627\u0646\u0636\u0645\u0627\u0645 \u0625\u0644\u0649 \u0634\u0631\u0643\u0629 Sentynl. \u0648\u0633\u062a\u0639\u0645\u0644 \u0634\u0631\u0643\u0629 PRF \u0639\u0646 \u0643\u062b\u0628 \u0645\u0639\u0647\u0645\u060c \u0643\u0645\u0627 \u0641\u0639\u0644\u0646\u0627 \u0645\u0639 \u0634\u0631\u0643\u0629 Eiger\u060c \u0644\u0644\u0645\u0633\u0627\u0639\u062f\u0629 \u0641\u064a \u062c\u0647\u0648\u062f \u0627\u0644\u0634\u0631\u0643\u0629 \u0644\u0636\u0645\u0627\u0646 \u0625\u0645\u062f\u0627\u062f Zokinvy \u062f\u0648\u0646 \u0627\u0646\u0642\u0637\u0627\u0639 \u0644\u0644\u0645\u0631\u0636\u0649 \u0641\u064a \u062c\u0645\u064a\u0639 \u0623\u0646\u062d\u0627\u0621 \u0627\u0644\u0639\u0627\u0644\u0645.\u00a0\u00a0<\/p>\n<p>\u064a\u0645\u0643\u0646 \u0627\u0644\u0639\u062b\u0648\u0631 \u0639\u0644\u0649 \u0631\u0627\u0628\u0637 \u0644\u0644\u0628\u064a\u0627\u0646 \u0627\u0644\u0635\u062d\u0641\u064a \u0627\u0644\u0630\u064a \u0623\u0635\u062f\u0631\u062a\u0647 \u0634\u0631\u0643\u0629 Sentynl \u062d\u0648\u0644 \u0647\u0630\u0627 \u0627\u0644\u062e\u0628\u0631 <a href=\"https:\/\/www.prnewswire.com\/news-releases\/sentynl-therapeutics-announces-global-acquisition-of-zokinvy-lonafarnib-for-treatment-of-hutchinson-gilford-progeria-syndrome-from-eiger-biopharmaceuticals-302135968.html\">\u0647\u0646\u0627<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"<p>\u0627\u0639\u062a\u0628\u0627\u0631\u064b\u0627 \u0645\u0646 \u064a\u0648\u0645 \u0627\u0644\u062c\u0645\u0639\u0629 3 \u0645\u0627\u064a\u0648\u060c \u0623\u0635\u0628\u062d\u062a \u0634\u0631\u0643\u0629 Sentynl Therapeutics \u0645\u0633\u0624\u0648\u0644\u0629 \u0639\u0646 \u062a\u0635\u0646\u064a\u0639 \u0648\u062a\u0648\u0632\u064a\u0639 Zokinvy\u060c \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0645\u0639\u062a\u0645\u062f \u0645\u0646 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0644\u0639\u0644\u0627\u062c \u0645\u0631\u0636 \u0627\u0644\u0634\u064a\u062e\u0648\u062e\u0629 \u0627\u0644\u0645\u0628\u0643\u0631\u0629. <\/p>","protected":false},"author":2,"featured_media":18808,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2,1],"tags":[],"class_list":["post-19165","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sentynl I The Progeria esearch Foundation<\/title>\n<meta name=\"description\" content=\"Effective Friday, May 3, Sentynl Therapeutics is responsible for the manufacture and distribution of Zokinvy, the FDA-approved treatment for Progeria.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/ar\/2024\/05\/04\/sentynl\/\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sentynl I The Progeria esearch Foundation\" \/>\n<meta property=\"og:description\" content=\"Effective Friday, May 3, Sentynl Therapeutics is responsible for the manufacture and distribution of Zokinvy, the FDA-approved treatment for Progeria.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/ar\/2024\/05\/04\/sentynl\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-04T19:39:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T14:23:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Karen Betournay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Progeria\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karen Betournay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"\u062f\u0642\u064a\u0642\u0629 \u0648\u0627\u062d\u062f\u0629\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/\"},\"author\":{\"name\":\"Karen Betournay\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\"},\"headline\":\"PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy\u00a9)\",\"datePublished\":\"2024-05-04T19:39:27+00:00\",\"dateModified\":\"2025-01-29T14:23:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/\"},\"wordCount\":266,\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\",\"articleSection\":[\"News\",\"Uncategorized\"],\"inLanguage\":\"ar\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/\",\"name\":\"Sentynl I The Progeria esearch Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\",\"datePublished\":\"2024-05-04T19:39:27+00:00\",\"dateModified\":\"2025-01-29T14:23:02+00:00\",\"description\":\"Effective Friday, May 3, Sentynl Therapeutics is responsible for the manufacture and distribution of Zokinvy, the FDA-approved treatment for Progeria.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\",\"width\":200,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.progeriaresearch.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy\u00a9)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ProgeriaResearch\/\",\"https:\/\/x.com\/Progeria\",\"https:\/\/www.instagram.com\/progeriaresearch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\",\"name\":\"Karen Betournay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"caption\":\"Karen Betournay\"},\"url\":\"https:\/\/www.progeriaresearch.org\/ar\/author\/karenb\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u0633\u064a\u0646\u062a\u064a\u0646\u0644 | \u0645\u0624\u0633\u0633\u0629 \u0623\u0628\u062d\u0627\u062b \u0627\u0644\u0634\u064a\u062e\u0648\u062e\u0629 \u0627\u0644\u0645\u0628\u0643\u0631\u0629","description":"\u0627\u0639\u062a\u0628\u0627\u0631\u064b\u0627 \u0645\u0646 \u064a\u0648\u0645 \u0627\u0644\u062c\u0645\u0639\u0629 3 \u0645\u0627\u064a\u0648\u060c \u0623\u0635\u0628\u062d\u062a \u0634\u0631\u0643\u0629 Sentynl Therapeutics \u0645\u0633\u0624\u0648\u0644\u0629 \u0639\u0646 \u062a\u0635\u0646\u064a\u0639 \u0648\u062a\u0648\u0632\u064a\u0639 Zokinvy\u060c \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0645\u0639\u062a\u0645\u062f \u0645\u0646 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0644\u0639\u0644\u0627\u062c \u0645\u0631\u0636 \u0627\u0644\u0634\u064a\u062e\u0648\u062e\u0629 \u0627\u0644\u0645\u0628\u0643\u0631\u0629.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/ar\/2024\/05\/04\/sentynl\/","og_locale":"ar_AR","og_type":"article","og_title":"Sentynl I The Progeria esearch Foundation","og_description":"Effective Friday, May 3, Sentynl Therapeutics is responsible for the manufacture and distribution of Zokinvy, the FDA-approved treatment for Progeria.","og_url":"https:\/\/www.progeriaresearch.org\/ar\/2024\/05\/04\/sentynl\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_published_time":"2024-05-04T19:39:27+00:00","article_modified_time":"2025-01-29T14:23:02+00:00","og_image":[{"width":200,"height":200,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","type":"image\/jpeg"}],"author":"Karen Betournay","twitter_card":"summary_large_image","twitter_creator":"@Progeria","twitter_site":"@Progeria","twitter_misc":{"Written by":"Karen Betournay","Est. reading time":"\u062f\u0642\u064a\u0642\u0629 \u0648\u0627\u062d\u062f\u0629"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#article","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/"},"author":{"name":"Karen Betournay","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946"},"headline":"PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy\u00a9)","datePublished":"2024-05-04T19:39:27+00:00","dateModified":"2025-01-29T14:23:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/"},"wordCount":266,"publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","articleSection":["News","Uncategorized"],"inLanguage":"ar"},{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/","url":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/","name":"\u0633\u064a\u0646\u062a\u064a\u0646\u0644 | \u0645\u0624\u0633\u0633\u0629 \u0623\u0628\u062d\u0627\u062b \u0627\u0644\u0634\u064a\u062e\u0648\u062e\u0629 \u0627\u0644\u0645\u0628\u0643\u0631\u0629","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","datePublished":"2024-05-04T19:39:27+00:00","dateModified":"2025-01-29T14:23:02+00:00","description":"\u0627\u0639\u062a\u0628\u0627\u0631\u064b\u0627 \u0645\u0646 \u064a\u0648\u0645 \u0627\u0644\u062c\u0645\u0639\u0629 3 \u0645\u0627\u064a\u0648\u060c \u0623\u0635\u0628\u062d\u062a \u0634\u0631\u0643\u0629 Sentynl Therapeutics \u0645\u0633\u0624\u0648\u0644\u0629 \u0639\u0646 \u062a\u0635\u0646\u064a\u0639 \u0648\u062a\u0648\u0632\u064a\u0639 Zokinvy\u060c \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0645\u0639\u062a\u0645\u062f \u0645\u0646 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0644\u0639\u0644\u0627\u062c \u0645\u0631\u0636 \u0627\u0644\u0634\u064a\u062e\u0648\u062e\u0629 \u0627\u0644\u0645\u0628\u0643\u0631\u0629.","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","width":200,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy\u00a9)"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"\u0645\u0624\u0633\u0633\u0629 \u0623\u0628\u062d\u0627\u062b \u0645\u0631\u0636 \u0627\u0644\u0634\u064a\u062e\u0648\u062e\u0629 \u0627\u0644\u0645\u0628\u0643\u0631\u0629","description":"\u0645\u0646 \u0623\u062c\u0644 \u0627\u0644\u0623\u0637\u0641\u0627\u0644 \u2665 \u0645\u0646 \u0623\u062c\u0644 \u0627\u0644\u0639\u0644\u0627\u062c","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"\u0645\u0624\u0633\u0633\u0629 \u0623\u0628\u062d\u0627\u062b \u0645\u0631\u0636 \u0627\u0644\u0634\u064a\u062e\u0648\u062e\u0629 \u0627\u0644\u0645\u0628\u0643\u0631\u0629","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]},{"@type":"Person","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946","name":"\u0643\u0627\u0631\u064a\u0646 \u0628\u064a\u062a\u0648\u0631\u0646\u0627\u064a","image":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","caption":"Karen Betournay"},"url":"https:\/\/www.progeriaresearch.org\/ar\/author\/karenb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/ar\/wp-json\/wp\/v2\/posts\/19165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ar\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ar\/wp-json\/wp\/v2\/comments?post=19165"}],"version-history":[{"count":0,"href":"https:\/\/www.progeriaresearch.org\/ar\/wp-json\/wp\/v2\/posts\/19165\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ar\/wp-json\/wp\/v2\/media\/18808"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/ar\/wp-json\/wp\/v2\/media?parent=19165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ar\/wp-json\/wp\/v2\/categories?post=19165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ar\/wp-json\/wp\/v2\/tags?post=19165"}],"curies":[{"name":"\u0648\u0648\u0631\u062f\u0628\u0631\u064a\u0633","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}